New study uncovers key insights into protein interactions in Duchenne muscular dystrophy, paving way for more targeted therapies

AURORA, Colo. (Dec. 31, 2024) – A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD).

Published in the December issue of the Journal of Biological Chemistry, researchers characterize the mysterious C-terminal (CT) domain of dystrophin and its role in stabilizing cellular membranes across various tissues.

DMD, a severe genetic disorder that causes muscle weakness and shortens lifespans, arises from mutations in the gene encoding dystrophin. While current treatments can extend patients’ lifespans, their high cost and limited efficacy underscore the urgent need for broader therapeutic approaches.

“This research highlights the intricate dynamics of dystrophin and dystrobrevin interactions, providing critical insights that could inform future treatment development,” said Krishna Mallela, professor of pharmaceutical sciences at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and study lead author. “By understanding how these proteins function differently in various tissues, we’re one step closer to designing treatments that target the root causes of DMD.”

The study reveals that dystrophin’s CT domain interacts differently with the two major dystrobrevin isoforms, which bind to dystrophin. Variations in the amino acid composition of dystrobrevin proteins drive differences in binding affinity and interaction modes, influencing the stability of the dystrophin-associated protein complex across tissues, a key indication of DMD.

These findings offer a molecular explanation for the wide-ranging symptoms experienced by DMD patients, which extend beyond skeletal muscles to affect organs such as the heart and brain.

“This discovery is exceptional in advancing DMD care because, while there have been advancements in therapies, they have been approved in desperation. We need to get to the root of things to really hone in on effective treatments,” says Mallela. “Much like a car engine, how can you fix a car without understanding how the car engine functions?”

About the University of Colorado Anschutz Medical Campus

The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado – which see more than two million adult and pediatric patient visits yearly. Innovative, interconnected and highly collaborative, the CU Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by $910 million in annual research funding, including $757 million in sponsored awards and $153 million in philanthropic gifts.